EQ

In the past six months, Equillium's stock price has experienced a general downward trend, falling by 11.03% over this period. However, there have been periods of positive movement. The stock climbed approximately 39% over a 30-day period and more than 60% over a quarter, driven by positive clinical updates and analyst actions. Key drivers included analyst price target increases and upgrades from firms such as Raymond James, Leerink, and Oppenheimer. Company-specific news on EQ504 progress in ulcerative colitis and a virtual investor event on the Aryl Hydrocarbon Receptor (AhR) pathway also supported sentiment. Significant events impacting the stock include: on August 13, 2026, Equillium reported its Second Quarter 2026 Financial Results and Recent Corporate Highlights, coinciding with a +17.16% stock price movement and the announcement of a $35 million private placement, extending its cash runway into 2029. On September 2, 2026, the company announced participation in upcoming investor conferences, leading to a +2.49% stock price movement. On September 16, 2026, Equillium announced participation in Stifel's 2026 Virtual Immunology and Inflammation Forum, which was followed by a -9.51% stock price movement. On September 19, 2026, Wall Street Zen downgraded Equillium from "Hold" to "Sell," although other analysts maintained more optimistic ratings.